Patients treated with on dupilumab showed significant improvement in sustained BP remission compared with those on placebo.

Dupilumab, an interleukin-4 receptor antagonist, is expected to decrease the type 2 inflammation seen in bullous pemphigoid.

As Sanofi and Regeneron await the FDA decision, a legal dispute between the partners over commercialisation details continues ...

Secured three additional regulatory approvals for world's first chikungunya vaccine, IXCHIQ ® (Canada, Europe, UK); filed adolescent label extension submissions; awarded new $41.3 million grant from ...

Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid If approved, Dupixent would be the first and only targeted medicine to treat BP in the US; FDA decision ...

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025 Priority Review granted based on positive pivotal results ...

Treatments that don’t involve drugs are also available. These may include talking therapies to help with depression or anxiety, and different forms of treatment (such as cognitive stimulation therapy) ...

A study led by UCL found that individuals with rare diseases were five times more likely to die from Covid-19 than the ...

There are a wide variety of treatment options to help you lose weight. Treatments include nutrition, exercise, medications, procedures, and other therapies that help people lose excess weight. A ...

Germany stands out within the EU4 and the UK with the highest Bullous Pemphigoid market value, reflecting its central role in the region's treatment landscape. As the market continues to evolve ...

At the moment there is one cannabis-based medicine that has been approved for treating epilepsy in the UK, called Epidyolex. It contains pure CBD and it does not contain any THC. Epidyolex is ...